Zongyang Yu

468 total citations
17 papers, 242 citations indexed

About

Zongyang Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Zongyang Yu has authored 17 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Zongyang Yu's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (3 papers). Zongyang Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (3 papers). Zongyang Yu collaborates with scholars based in China and United States. Zongyang Yu's co-authors include Zhengbo Song, C. Xu, Wenxian Wang, Pei‐Hua Lu, Hong Wang, Wenwu Wang, Wu Zhuang, Ying Chen, Guoxiang Lai and Shuiliang Wang and has published in prestigious journals such as PLoS ONE, Biomedicine & Pharmacotherapy and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Zongyang Yu

16 papers receiving 239 citations

Peers

Zongyang Yu
Se-Kyung Lee South Korea
Yongshun Chen China
Xiaona Lu China
Renwang Liu China
Mingyan He China
Xiaomin Liu China
Cristina Eunbee Cho South Korea
Hai-biao Yan China
Se-Kyung Lee South Korea
Zongyang Yu
Citations per year, relative to Zongyang Yu Zongyang Yu (= 1×) peers Se-Kyung Lee

Countries citing papers authored by Zongyang Yu

Since Specialization
Citations

This map shows the geographic impact of Zongyang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zongyang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zongyang Yu more than expected).

Fields of papers citing papers by Zongyang Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zongyang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zongyang Yu. The network helps show where Zongyang Yu may publish in the future.

Co-authorship network of co-authors of Zongyang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Zongyang Yu. A scholar is included among the top collaborators of Zongyang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zongyang Yu. Zongyang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Huang, Qian, Peng Zhang, Zheng Guo, et al.. (2024). Comprehensive analysis of transcriptomics and radiomics revealed the potential of TEDC2 as a diagnostic marker for lung adenocarcinoma. PeerJ. 12. e18310–e18310. 1 indexed citations
2.
Chen, Ying, et al.. (2022). Genetic alteration and PD-L1 expression profiles of Chinese patients with lung squamous cell carcinoma. Pathology - Research and Practice. 231. 153761–153761.
3.
Wang, Jingfang, et al.. (2022). Silencing LncRNA CASC9 inhibits proliferation and invasion of colorectal cancer cells by MiR-542-3p/ILK. PLoS ONE. 17(4). e0265901–e0265901. 5 indexed citations
4.
Wang, Wenxian, Zhangzhou Huang, Zongyang Yu, et al.. (2020). Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Frontiers in Oncology. 10. 572853–572853. 18 indexed citations
5.
Pu, Xingxiang, Liping Wang, Zongyang Yu, et al.. (2020). Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. Clinical Lung Cancer. 21(5). e349–e354. 27 indexed citations
6.
Song, Zhengbo, Zongyang Yu, Qing Shen, et al.. (2020). The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 48(2). 361–371. 33 indexed citations
7.
Chen, Ying, Xiaoli Wu, Zhongquan Zhao, et al.. (2020). Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway. International Journal of Molecular Medicine. 45(4). 1213–1224. 36 indexed citations
8.
Wang, Wenxian, Hong Wang, Pei‐Hua Lu, et al.. (2019). Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. Journal of Translational Medicine. 17(1). 52–52. 28 indexed citations
9.
Lin, Xiandong, Yan Xia, Dan Hu, et al.. (2019). Transcriptome‑wide piRNA profiling in human gastric cancer. Oncology Reports. 41(5). 3089–3099. 27 indexed citations
10.
Du, Bin, et al.. (2018). Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment. OncoTargets and Therapy. Volume 11. 9111–9116. 11 indexed citations
11.
Song, Zhengbo, Hong Wang, Zongyang Yu, et al.. (2018). De Novo MET Amplification in Chinese Patients With Non–Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study. Clinical Lung Cancer. 20(2). e171–e176. 21 indexed citations
12.
Wang, Shaohua, Nan Li, Yan‐Ming Xie, et al.. (2014). [Improvement of survival quality of the patients with hemodialysis treated with moxibustion for regulating spleen and stomach functions: multi-central randomized controlled study].. PubMed. 34(4). 319–24. 1 indexed citations
13.
Xie, Fangwei, Xi Chen, Xiong Chen, et al.. (2013). Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. Biomedicine & Pharmacotherapy. 68(1). 31–37. 6 indexed citations
14.
Chen, Xiong, Zengfu Xue, Jie Li, et al.. (2013). CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. APOPTOSIS. 18(7). 861–869. 17 indexed citations
15.
Wang, Wenwu, Xuenong Ouyang, Xi Chen, & Zongyang Yu. (2013). Initial outcome of induction chemotherapy followed by radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer. The Chinese-German Journal of Clinical Oncology. 12(7). 310–314. 1 indexed citations
16.
Liu, Zhizhen, et al.. (2012). Applied research on serum protein fingerprints for prediction of Qi deficiency syndrome and phlegm and blood stasis in patients with non-small cell lung cancer. Journal of Traditional Chinese Medicine. 32(3). 350–354. 8 indexed citations
17.
Yu, Zongyang, Zhizhen Liu, Xuenong Ouyang, et al.. (2012). Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer. Chinese Journal of Integrative Medicine. 18(2). 106–111. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Se-Kyung Lee Breakdown of academic impact, for papers by Yongshun Chen Breakdown of academic impact, for papers by Xiaona Lu Breakdown of academic impact, for papers by Renwang Liu Breakdown of academic impact, for papers by Mingyan He Breakdown of academic impact, for papers by Xiaomin Liu Breakdown of academic impact, for papers by Cristina Eunbee Cho Breakdown of academic impact, for papers by Hai-biao Yan
Rankless by CCL
2026